Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Treasury Shares (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Treasury Shares for 9 consecutive years, with $417772.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares fell 29.87% to $417772.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $417772.0 through Dec 2025, down 29.87% year-over-year, with the annual reading at $417772.0 for FY2025, 29.87% down from the prior year.
  • Treasury Shares hit $417772.0 in Q4 2025 for Sutro Biopharma, down from $5.2 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $6.2 million in Q2 2025 to a low of $417772.0 in Q4 2025.
  • Historically, Treasury Shares has averaged $4.0 million across 5 years, with a median of $3.9 million in 2022.
  • Biggest five-year swings in Treasury Shares: skyrocketed 260.73% in 2021 and later plummeted 88.64% in 2024.
  • Year by year, Treasury Shares stood at $2.4 million in 2021, then soared by 64.67% to $4.0 million in 2022, then skyrocketed by 32.5% to $5.2 million in 2023, then tumbled by 88.64% to $595691.0 in 2024, then fell by 29.87% to $417772.0 in 2025.
  • Business Quant data shows Treasury Shares for STRO at $417772.0 in Q4 2025, $5.2 million in Q3 2025, and $6.2 million in Q2 2025.